ACCESS & SUPPORT
PATIENT SOLUTIONS PROGRAM
MONOFERRIC PATIENT SOLUTIONS DELIVERS DIVERSE SUPPORT TO HELP ADDRESS IDA TREATMENT NEEDS
COVERAGE AND ACCESS INFORMATION
- Live representatives available
- Benefits verification/investigation
- Prior Authorization support
- Buy and bill information
- Claims and appeals assistance
- HCP Portal for patient enrollment
To learn more, call 800-992-9022.
[Monday–Friday: 8 AM–8 PM ET]
- Billing and coding guide
- Sample annotated claim forms
- Sample letters of appeal and medical necessity
SUPPLEMENTAL NURSING PROGRAM
- Virtual live peer to peer nursing support
- Patient care support for enrolled patients
REQUEST NURSE SUPPORT
- Available for patients with commercial health insurance*
- On-demand support to assist with your patient reimbursement needs
- Patient benefits verification
- Case follow-up
REQUEST TO TALK TO A REPRESENTATIVE
Patient Assistance Program available for patients who are underinsured or uninsured
*Cash paying patients may also qualify
PLEASE DIRECT MEDICAL INFORMATION REQUESTS TO 888-828-0655 OR MEDINFO@PHARMACOSMOS.US AND FOR ANY OTHER QUESTIONS, PLEASE CONTACT THE MONOFERRIC PATIENT SOLUTIONS PROGRAM AT 800-922-9022 OR VISIT MONOFERRIC-PATIENT-SOLUTIONS.COM
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:
- who have intolerance to oral iron or have had unsatisfactory response to oral iron
- who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)
IMPORTANT SAFETY INFORMATION
Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.
Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload.
Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.
References: 1. Monoferric (ferric derisomaltose) Prescribing Information; Pharmacosmos Therapeutics Inc., Morristown, NJ: 2020. 2. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. Am J Hematol. 2019;94(9):1007‐1014.